KemPharm (NASDAQ: KMPH) is a clinical-stage specialty pharmaceutical company that discovers and develops new proprietary prodrugs in the United States through its proprietary Ligand Activated Therapy (“LATTM”) platform technology. KemPharm’s co-lead clinical development candidates are KP415 and KP484, both based on a prodrug of methylphenidate, but with differing extended-release and effect profiles for the treatment of ADHD. Apadaz™, the company’s product candidate of benzhydrocodone, a prodrug of hydrocodone and acetaminophen, has received FDA approval. The company is also involved in developing KP201/IR (APAP-free), an IR formulation of KP201 without APAP for the short-term management of acute pain. For more information, visit the company’s website at www.kenpharm.com.
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.networknewswire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.networknewswire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
